Poster

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD). Valbenaz...

08/20/2024

Education to Improve Treatment-Resistant Depression Diagnosis in the Outpatient Behavioral Health Setting

Abstract: Treatment-resistant depression can be difficult to identify in the outpatient behavioral health setting due to a lack of clear diagnostic guidelines. The evidence-based improvem...

08/20/2024

When the treatment for psychogenic polydipsia backfires: the analysis of clozapine-induced neuroleptic malignant syndrome

Abstract: Our case involves a 64-year-old male with a past psychiatric history of schizoaffective disorder (bipolar type; on clozapine 400mg nightly) and who presented to the hospital for...

08/20/2024

Variables Associated with Remission in Patients Treated with Esketamine Nasal Spray or Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study

Abstract: Objective: To examine baseline and disease characteristics of patients with treatment-resistant depression (TRD) who achieved remission at week 8 with quetiapine extended releas...

08/20/2024

TMS use in neurological complications following Covid-19 vaccination.

Abstract: Abstract Background Neurological complications after covid-19 are well described. TMS plays a role in the treatment of this condition. However, the use of TMS in neurological co...

08/20/2024

Treating Major Depressive Disorder After Suboptimal Response to Antidepressant Treatment: Where Do Digital Mental Health Tools Fit in?

Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next tre...

08/20/2024

Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: Post-Hoc Analyses of Two Phase 3 Clinical Trials

Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). Valbenazine effect sizes (Cohen’s d) for th...

08/20/2024

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

Abstract: Background: The long-acting injectable aripiprazole lauroxil (AL) initiated using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg dose of ...

08/20/2024

Treatment Patterns and Persistence Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence. Underst...

08/20/2024